Predict your next investment

Zenith Epigenetics company logo
HEALTHCARE | Biotechnology
zenithepigenetics.com

See what CB Insights has to offer

Founded Year

2013

Stage

Milestone Payment | Alive

Total Raised

$5M

Last Raised

$5M | 2 yrs ago

About Zenith Epigenetics

Zenith Epigenetics is a clinical stage biotechnology company that developes bromodomain inhibitors for the treatment of cancer and other disorders with significant unmet medical need.

Zenith Epigenetics Headquarter Location

300, 4820 Richard Road SW

Calgary, Alberta, T3E 6L1,

Canada

587-390-7865

Latest Zenith Epigenetics News

Zenith Epigenetics Announces a Publication in the Journal of Cancer Gene Therapy with Compelling Data for the Treatment of ER-Positive Breast Cancer Patients

Aug 17, 2021

Calgary, Alberta, CANADA CALGARY, Alberta, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”), a clinical stage biotechnology company focused on the development of novel epigenetic combination therapies for the treatment of cancers, announces a publication in the high-impact Nature Publishing Group journal of Cancer Gene Therapy, titled: “Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer.” This important study highlights the potential for ZEN-3694 in combination with CDK4/6 inhibitors as a new therapeutic option for patients with advanced ER+ breast cancer who developed resistance to current therapies. The study shows that the combination can reverse acquired CDK4/6i resistance by targeting key oncogenic pathways involved in cell cycle regulation, cellular growth, proliferation, apoptosis, inflammation, and cellular immune response. Additionally, ZEN-3694 down-regulated markers involved in CDK4/6 inhibitor resistance including CDK6, CCND1, CDK4, MYC, ESR1 and others. Notably, the combination led to the synergistic increase of apoptosis and inhibition of proliferation in the resistant ER+ breast cancer models. The publication can be viewed using the following LINK . “This compelling data highlights the role of ZEN-3694 in the potential treatment of patients with advanced ER+ breast cancer, leading to the reversal of the acquired resistance to the current standard of care therapies,” said Donald McCaffrey, President and Chief Executive Officer of Zenith. “As there is a significant unmet need in this population, this study reveals the huge potential in this indication and rationale for a future clinical trial.” About ER+ Breast Cancer According to Cancer Statistics, 2021 , Estrogen receptor-positive breast cancer (ER+) is a prevalent disease with over two million global new cases diagnosed in 2020. Approximately 70–80% of women diagnosed with breast cancer are ER+. The standard of care for metastatic ER+ breast cancer patients include selective estrogen receptor modulators, estrogen receptor degraders, aromatase inhibitors, as well as a combination of endocrine therapy with inhibitors of cyclin-dependent kinases (CDK4/6 inhibitors, CDK4/6i). Three approved CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) have been shown to significantly improve progression-free survival in combination with endocrine therapy for the treatment of metastatic breast cancer patients. Although significant advances have been made in treating metastatic ER+ breast cancer, resistance to therapies invariably occurs over time, making it essential to develop new therapies that address resistance. About Zenith Zenith Capital Corp. is a biotechnology investment company originally spun out of Resverlogix Corp. (TSX: RVX) in 2013. Zenith Epigenetics Ltd., a wholly-owned subsidiary of Zenith Capital Corp., is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with significant unmet medical need. Zenith Epigenetics is developing various novel combinations of BET inhibitors with other targeted agents. The lead compound, ZEN-3694, is in clinical development for: mCRPC in combination with androgen receptor inhibitor, XTANDI, with Astellas and Newsoara as collaborators Triple Negative Breast Cancer in combination with the PARP inhibitor TALZENNA with Pfizer as a collaborator Androgen receptor independent mCRPC in combination with immune checkpoint inhibitor KEYTRUDA and XTANDI with University of California, San Francisco as a collaborator For further information, please contact: Investor Relations & Communications

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Zenith Epigenetics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Zenith Epigenetics is included in 2 Expert Collections, including Biopharmaceuticals.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,592 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Zenith Epigenetics Patents

Zenith Epigenetics has filed 13 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Experimental cancer drugs
  • Oncology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/18/2019

6/8/2021

Transcription factors, Oncology, Rare diseases, Experimental cancer drugs, Clusters of differentiation

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

1/18/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

6/8/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Transcription factors, Oncology, Rare diseases, Experimental cancer drugs, Clusters of differentiation

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Zenith Epigenetics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Zenith Epigenetics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.